L-Kynurenine

Catalog No.S5839 Batch:S583902

Technical Data

Formula

C₁₀H₁₂N₂O₃

Molecular Weight

208.21

CAS No.

2922-83-0

Solubility (25°C)*

In vitro

DMSO

21 mg/mL (100.85 mM)

Water

14 mg/mL (67.23 mM)

Ethanol

Insoluble

In vivo (Add solvents to the product individually and in order)

Clear solution	5% DMSO 1 95% Corn oil	1.05mg/ml	Taking the 1 mL working solution as an example, add 50 μL of 21 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Clear solution	saline	10.0mg/ml	Taking the 1 mL working solution as an example, add 10 mg of this product to 1 ml of physiological saline (0.9% NaCL solution), mix evenly to make it clear, The mixed solution should be used immediately for optimal results.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O	1.05mg/ml	Taking the 1 mL working solution as an example, add 50 μL of 21 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description	L-Kynurenine ((S)-Kynurenine) is a aryl hydrocarbon receptor agonist. L-Kynurenine is a metabolite of the amino acid L-tryptophan used in the production of niacin and a central compound of the tryptophan metabolism pathway.
In vitro	Kynurenine (Kyn), the tryptophan (Trp) metabolite and an AHR ligand in hepatocytes, accumulates to cellular levels to cause an elevated rate of AHR activation, and stimulates AHR transcriptional activity quickly. An excess production of Kyn via increased cellular IDO1 levels and activity leads to amplified AHR signaling ultimately giving rise to obesity.^[1]
In vivo	L-kynurenine shows a dose-dependent significant neuroprotective effect before the hypoxia-ischemia of rats, and blocks the induction of c-fos immunoreactivity in cerebral cortex following ischemia.^[2]

Protocol (from reference)

Cell Assay:^{^[1]}	Cell lines H1L7.5c3 mouse hepatocytes Concentrations 0.1, 1, 10, 100 μM Incubation Time 24 h Method H1L7.5c3 cells are seeded in white-walled, white-bottomed 96-well plates at 4000 cells/well and incubated for 24 hr in culture medium. After the 24-hr incubation, the medium is removed, and the cells are washed once with Dulbecco's Phosphate Buffered Saline. Cells are treated with Kynurenine (Kyn) for an additional 24 hr, all of which are dissolved in DMSO unless otherwise noted. Then, cells are removed from incubation and allowed to equilibrate to room temperature for 15min. After equilibration, the medium is removed and the cells are washed twice with at room temperature with DPBS. The cells are lysed with 20 μl/well 1 Passive Lysis Buffer and shaken for 20 min at room temperature. Luciferase activity is recorded programmed to inject 50 μl Luciferase Assay Reagent per well with a 10 sec integration of emitted luminescence.
Animal Study:^{^[2]}	Animal Models 7-day-old rats Dosages 100, 200, or 300 mg/kg; 50, 100, 200, 300, 400 mg/kg Administration i.p.

Cell Assay:^{^[1]}

Cell lines
H1L7.5c3 mouse hepatocytes
Concentrations
0.1, 1, 10, 100 μM
Incubation Time
24 h
Method
H1L7.5c3 cells are seeded in white-walled, white-bottomed 96-well plates at 4000 cells/well and incubated for 24 hr in culture medium. After the 24-hr incubation, the medium is removed, and the cells are washed once with Dulbecco's Phosphate Buffered Saline. Cells are treated with Kynurenine (Kyn) for an additional 24 hr, all of which are dissolved in DMSO unless otherwise noted. Then, cells are removed from incubation and allowed to equilibrate to room temperature for 15min. After equilibration, the medium is removed and the cells are washed twice with at room temperature with DPBS. The cells are lysed with 20 μl/well 1 Passive Lysis Buffer and shaken for 20 min at room temperature. Luciferase activity is recorded programmed to inject 50 μl Luciferase Assay Reagent per well with a 10 sec integration of emitted luminescence.

Animal Study:^{^[2]}

Animal Models
7-day-old rats
Dosages
100, 200, or 300 mg/kg; 50, 100, 200, 300, 400 mg/kg
Administration
i.p.

References

Selleck's L-Kynurenine has been cited by 1 publication

A novel lncRNA linc-AhRA negatively regulates innate antiviral response in murine microglia upon neurotropic herpesvirus infection [ Theranostics, 2021, 11(19):9623-9651]	PubMed: 34646390

A novel lncRNA linc-AhRA negatively regulates innate antiviral response in murine microglia upon neurotropic herpesvirus infection [ Theranostics, 2021, 11(19):9623-9651]

PubMed: 34646390

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.